UniQure Faces Shareholder Lawsuit Over Pivotal Study
Analysis based on 8 articles · First reported Feb 11, 2026 · Last updated Mar 05, 2026
The market is likely to react negatively to UniQure due to the shareholder lawsuit, potentially leading to a decrease in its stock price. This event highlights the risks associated with regulatory approval processes in the biotechnology sector.
A shareholder class action lawsuit has been filed against UniQure, a biotechnology company. The lawsuit alleges that UniQure made false and misleading statements and failed to disclose material adverse facts concerning its Pivotal Study. Specifically, it claims that the study's design, including the comparison to the ENROLL-HD external historical data set, was not fully approved by the United States===Food and Drug Administration. Furthermore, the lawsuit asserts that UniQure downplayed the probability of delaying its Biologics License Application timeline, despite purportedly successful study results, to perform additional supplementary studies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard